| Catalog No. | HV217026 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
SLAMF7, CRACC, Protein 19A, SLAM family member 7, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, CD319, Novel Ly9, CD2 subset 1, CS1 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
Q9NQ25 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | ABBV-383, PR-1471272, ABBV-838, 1826819-57-1 |
|---|
| Background | Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.
• SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin., PMID:28424516
• 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer., PMID:30347240
• CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma., PMID:23731618
• CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes., PMID:17878365
• The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders., PMID:40073958
• Hematologic Malignancies: Plasma Cell Disorders., PMID:28561703
• Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma., PMID:28356715
• 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes., PMID:11513145
• Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma., PMID:39060023
• Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma., PMID:27533882
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
